|
市場調查報告書
競爭分析:抗感染抗體
Competitor Analysis: Anti-Infective Antibodies
|
競爭分析:抗感染抗體 是由出版商La Merie Publishing在2011年11月所出版的。
這份英文市場調查報告書包含160 Pages 價格從美金1086起跳。
本報告提供重組單株與多株抗體、人血漿內免疫球蛋白各相關企業調查分析，彙整產品系列，R&D相關的目前企劃趨勢等資料，為您概述為以下內容。
用於病毒疾病的重組抗體
- 呼吸器合胞體(RS)病毒
- HIV
- C型肝炎病毒
- 狂犬病病毒
- 流感病毒
- 單純疱疹（皰疹）病毒
- 出血熱病毒
- 巨細胞病毒
- 其他各種病毒
- 對付不明病毒的廣泛性抗病毒劑
用於細菌性疾病的重組抗體
- 炭疽菌
- 葡萄球菌
- 假單胞菌
- 鏈球菌
- 梭狀桿菌
- 肉毒桿菌
- 其他各種細菌
- 對付不明細菌的廣泛性抗菌劑
用於寄生蟲性疾病的重組抗體
人血漿內免疫球蛋白
- 傳統静脈内免疫球蛋白(IVIG)
- 濃縮免疫球蛋白
- 注入型SC/IM免疫球蛋白
- 口服免疫球蛋白
特定的免疫球蛋白
- 水痘帶狀疱疹免疫球蛋白(VZIG)
- 破傷風免疫球蛋白
- 狂犬病免疫球蛋白
- B型肝炎免疫球蛋白
- A型肝炎免疫球蛋白
- 巨細胞・病毒
- 牛痘（痘苗病毒）
- 其他各種免疫球蛋白
企業的抗感染抗體投資組合·R&D管線
Abstract
Summary
Product description
The present Competitive Intelligence Report about Anti-Infective Antibodies
provides a competitor evaluation in the field of recombinant monoclonal and
polyclonal antibodies and human plasma-derived immunoglobulins and
hyperimmunes for post-exposure prophylaxis and treatment of infectious
diseases as of November 2011. Purchase of the downloadable pdf report includes
a 6-month online access to the data of the report and any updates since the
publication date. Credentials to access the database will be sent by e-mail
and allow online work with the project data to print or export an individual
report.
The emergence of antibiotic resistant microorganisms, lethal viruses and the
threat of engineered microorganism have newly stimulated the interest in
recombinant antibodies for infectious diseases. Advances in understanding
pathogenetic mechanisms and new antibody technologies have further contributed
to a growing class of anti-infective antibodies. Apart from recombinant mono-
or polyclonal antibodies, human plasma-derived immunoglobulins have their
place in the treatment of immunedeficiencies and specific immunoglobulins
(hyperimmunes) are part of standard protocols in post-exposure prophylaxis of
a number of infectious diseases. Modern plasma-derived immunoglobulins are
characterized by improved purification procedures, more convenience (room
temperature stable, ready-to-use preparations, new stabilizers, higher
concentrated) and new developments.
The report includes a compilation of product portfolios and current active
projects in research and development of anti-infective antibodies and
immunoglobulins. In addition, the report lists company-specific R&D pipelines
product portfolios anti-infective antibodies, immunoglobulins and
hyperimmunes. Competitor projects are listed in a tabular format providing
information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information
about the pipeline of R&D projects for targets, diseases, technologies and
companies at low prices. The information is provided in a tabular format and
fully referenced.
Table of Contents
Recombinant Antibodies for Viral Diseases
- Respiratory Syncytial Virus (RSV)
- Human Immune Deficiency Virus (HIV)
- Hepatitis C Virus (HCV)
- Rabies Virus
- Influenza Virus
- Herpes Simplex Virus
- Hemorrhagic Fever Viruses
- Cytomegalovirus (CMV)
- Various Viruses
- Unspecified Virus, Broad Spectrum Antiviral Antibodies
Recombinant Antibodies for Bacterial Diseases
- Bacillus Anthracis
- Staphylococci
- Pseudomonas
- Streptococci
- Clostridium Difficile
- Clostridium Botulinum
- Various Bacteria
- Unspecified Bacteria, Broad Spectrum Antibacterial Antibodies
Recombinant Antibodies for Parasitic Diseases
Human Plasma-Derived Immunoglobulins
- Conventional Intravenous Immunoglobulins (IVIG)
- Enriched Immunoglobulins
- Injectable SC/IM Immunoglobulins
- Oral Immunoglobulins
Specific Immunoglobulins (Hyperimmunes)
- Varicella Zoster Immunoglobulins (VZIG)
- Tetanus Immunoglobulins
- Rabies Immunoglobulins
- Hepatitis B Immunoglobulins
- Hepatitis A Immunoglobulins
- Cytomegalovirus Immunoglobulins
- Vaccinia Immunoglobulins
- Various Immunoglobulins
Corporate Anti-Infective Antibody Portfolios and R&D Pipelines
|
